<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04432402</url>
  </required_header>
  <id_info>
    <org_study_id>2019-SR-443</org_study_id>
    <nct_id>NCT04432402</nct_id>
  </id_info>
  <brief_title>Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma</brief_title>
  <official_title>Efficacy and Safety of Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate efficacy and safety of Lenalidomide in
      combination with R-GemOx as first-line treatment of elderly patients with Diffuse large B
      cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gemcitabine and Oxaliplatin(GemOx) shows effective activity in patients with relapsed diffuse
      large-cell lymphoma and other solid tumors. The purpose of this study is to investigate
      efficacy and safety of Lenalidomide in combination with R-GemOx as first-line treatment of
      elderly patients with Diffuse large B cell lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 14, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>at the end of the first cycle of R2-GemOx (each cycle is 14 days)</time_frame>
    <description>Maximum tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>28 days</time_frame>
    <description>Dose limiting toxicity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>Dose limiting toxicity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Lenalidomide in Combination With R-GemOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide 10mg、15mg、20mg、25mg qd PO d1-7 Rituximab 375mg/m2 ivd d0 Gemcitabine 1g/m2 ivd d1 Oxaliplatin 100mg/m2 ivd d1 every14 days as a cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Lenalidomide: 10mg、15mg、20mg、25mg qd PO day 1-7, Rituximab: 375 mg/m2 IV day0, Gemcitabine :1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1 (every 14 days as a cycle)</description>
    <arm_group_label>Lenalidomide in Combination With R-GemOx</arm_group_label>
    <other_name>Rituximab, Gemcitabine, oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The histopathologic diagnosis was DLBCL (except primary mediastinal large B cell
             lymphoma, primary central lymphoma, HIV related lymphoma).

          2. Age older than 70 years or older than 60 years with Eastern Cooperative Oncology
             Group(ECOG) performance status(PS) ≥ 2;

          3. Expected survival ≥ 12 weeks;

          4. At least a measurable or evaluable disease at the time of enrolment (diameter ≥1.5cm);

          5. Understand and voluntarily sign an informed consent form, able to adhere to the study
             visit schedule and other protocol requirements;

          6. All patients must agree to take effective contraceptive measures during the trial
             measures

        Exclusion Criteria:

          1. Active hepatitis B or hepatitis C virus infection, as well as acquired, congenital
             immune deficiency diseases, including but not limited to HIV infected persons

          2. Patients known to have varicella or herpes zoster virus infection

          3. Previous exposure to any anti-tumor therapy

          4. Poor hepatic and/or renal function, unless these abnormalities were related to the
             lymphoma

          5. Poor bone-marrow reserve, defined as neutrophil count less than 1.5×109/L or platelet
             count less than 75×109/L, unless caused by bone marrow infiltration

          6. History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within past 12 months

          7. New York Heart Association class III or IV cardiac failure; or Ejection fraction less
             than 50%;or history of following disease in past 6 months: acute coronary
             syndrome#acute heart failure#severe ventricular arrhythmia

          8. Central nervous system (CNS) or meningeal involvement

          9. Known sensitivity or allergy to investigational product

         10. Major surgery within three weeks

         11. Patients receiving organ transplantation

         12. Patients with secondary tumour, excluding cured (5 years without relapse) in situ
             Non-melanoma skin cancer. superficial bladder cancer, in situ cervical cancer,
             Gastrointestinal intramucous carcinoma and breast cancer

         13. Presence of Grade III nervous toxicity within past two weeks

         14. Active and severe infectious diseases

         15. Any potential drug abuse, medical, psychological or social conditions which may
             disturb this investigation and assessment

         16. In any conditions which investigator considered ineligible for this study.

         17. Histologic transformation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Xu, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Wang, M.D</last_name>
    <phone>+862568136034</phone>
    <email>lilyw7878@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Xu, M.D., Ph.D</last_name>
    <phone>+862568136034</phone>
    <email>xuwei0484@jsph.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital)</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Wang, M.D., Ph.D</last_name>
      <phone>86 25 68306034</phone>
      <email>lilyw7878@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wei Xu, M.D., Ph.D</last_name>
      <phone>86 25 68306034</phone>
      <email>xuwei10000@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>June 13, 2020</last_update_submitted>
  <last_update_submitted_qc>June 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>WEI XU</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>R-Gemox</keyword>
  <keyword>Lenalidomide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

